Back to Search
Start Over
XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer
- Source :
- PLoS ONE, PLoS ONE, Vol 7, Iss 3, p e31601 (2012)
- Publication Year :
- 2011
-
Abstract
- Background Approximately 60–80% of patients with advanced head and neck squamous cell carcinoma (HNSCC) die within five years after diagnosis. Cisplatin-based chemotherapy is the most commonly used palliative treatment for these patients. To evaluate the prognostic value of X-linked inhibitor of apoptosis (XIAP) level as a potential biomarker in these patients, we investigated the relationship between XIAP expression and cisplatin response of these patients and their prognosis. Methodology/Principal Findings Sixty patients with advanced HNSCC were recruited in this study. Expression of XIAP was examined both before and after chemotherapy and was correlated with chemotherapy response, clinicopathology parameters and clinical outcomes of the patients. We found that XIAP was expressed in 17 (20.83%) of the 60 advanced HNSCC samples and the expression was significantly associated with cisplatin resistance (P = 0.036) and poor clinical outcome (P = 0.025). Cisplatin-based chemotherapy induced XIAP expression in those post-chemotherapy samples (P = 0.011), was further associated with poorer clinical outcome (P = 0.029). Multivariate analysis demonstrated that only alcohol consumption, lymph node metastasis and XIAP level were independently associated with the prognosis of advanced HNSCC patients. Inhibiting XIAP expression with siRNA in XIAP overexpressed HNSCC cells remarkably increased their sensitivity to cisplatin treatment to nearly a 3 fold difference. Conclusions/Significance Our results demonstrate that XIAP overexpression plays an important role in the disease course and cisplatin-resistance of advanced HNSCC. XIAP is a valuable predictor of cisplatin-response and prognosis for patients with advanced head and neck cancer. Down-regulation of XIAP might be a promising adjuvant therapy for those patients of advanced HNSCC.
- Subjects :
- Oncology
Male
medicine.medical_specialty
Pathology
medicine.medical_treatment
Cancer Treatment
lcsh:Medicine
Antineoplastic Agents
X-Linked Inhibitor of Apoptosis Protein
Inhibitor of apoptosis
Diagnostic Medicine
Internal medicine
Cell Line, Tumor
Adjuvant therapy
Medicine
Neoplasm
Humans
lcsh:Science
Neoplasm Staging
Cisplatin
Chemotherapy
Multidisciplinary
Base Sequence
business.industry
lcsh:R
Head and neck cancer
Cancers and Neoplasms
medicine.disease
Prognosis
Head and neck squamous-cell carcinoma
Head and Neck Tumors
XIAP
Gene Expression Regulation, Neoplastic
Treatment Outcome
Otorhinolaryngology
Drug Resistance, Neoplasm
Head and Neck Neoplasms
lcsh:Q
Female
business
medicine.drug
Research Article
General Pathology
Subjects
Details
- ISSN :
- 19326203
- Volume :
- 7
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- PloS one
- Accession number :
- edsair.doi.dedup.....845e280170a6e120760e1ba804577080